No abstract

Information related to the diverse and dynamic metabolite composition of the small intestine is crucial for the diagnosis and treatment of various diseases. However, our current understanding of the physiochemical dynamics of metabolic processes within the small intestine is limited due to the lack of in situ access to the intestinal environment. Here, we report a demonstration of a battery-free ingestible biosensing system for monitoring metabolites in the small intestine. As a proof of concept, we monitor the intestinal glucose dynamics on a porcine model. Battery-free operation is achieved through a self-powered glucose biofuel cell/biosensor integrated into a circuit that performs energy harvesting, biosensing, and wireless telemetry via a power-to-frequency conversion scheme using magnetic human body communication. Such long-term biochemical analysis could potentially provide critical information regarding the complex and dynamic small intestine metabolic profiles.

Levodopa (L‐Dopa) is the “gold‐standard” medication for symptomatic therapy of Parkinson disease (PD). However, L‐Dopa long‐term use is associated with the development of motor and non‐motor complications, primarily due to its fluctuating plasma levels in combination with the disease progression. Herein, we present the first example of individualized therapeutic drug monitoring for subjects upon intake of standard L‐Dopa oral pill, centered on dynamic tracking of the drug concentration in naturally secreted fingertip sweat. The touch‐based non‐invasive detection method relies on instantaneous collection of fingertip sweat on a highly permeable hydrogel that transports the sweat to a biocatalytic tyrosinase‐modified electrode, where sweat L‐Dopa is measured by reduction of the dopaquinone enzymatic product. Personalized dose‐response relationship is demonstrated within a group of human subjects, along with close pharmacokinetic correlation between the finger touch‐based fingertip sweat and capillary blood samples.

Levodopa (L‐Dopa) is the “gold‐standard” medication for symptomatic therapy of Parkinson disease (PD). However, L‐Dopa long‐term use is associated with the development of motor and non‐motor complications, primarily due to its fluctuating plasma levels in combination with the disease progression. Herein, we present the first example of individualized therapeutic drug monitoring for subjects upon intake of standard L‐Dopa oral pill, centered on dynamic tracking of the drug concentration in naturally secreted fingertip sweat. The touch‐based non‐invasive detection method relies on instantaneous collection of fingertip sweat on a highly permeable hydrogel that transports the sweat to a biocatalytic tyrosinase‐modified electrode, where sweat L‐Dopa is measured by reduction of the dopaquinone enzymatic product. Personalized dose‐response relationship is demonstrated within a group of human subjects, along with close pharmacokinetic correlation between the finger touch‐based fingertip sweat and capillary blood samples.

No abstract